CS Genetics Welcomes Paul McEwan as New Independent Board Director

Recently, CS Genetics, a prominent figure in single-cell genomics, proclaimed the addition of Paul McEwan as an Independent Director to its board. With over 20 years of experience in the life sciences sector, McEwan's expertise is expected to bolster the company's strategic initiatives and innovations.

A Track Record of Innovation

Mr. McEwan is not new to the biotechnology landscape; he is a seasoned entrepreneur known for his leadership in founding and expanding successful biotech ventures. His notable achievements include co-founding Kapa Biosystems, where he served as the Chief Scientific Officer until its acquisition by Roche in 2015. During his tenure, Kapa pioneered high-performance reagents that drastically improved the efficiency and effectiveness of life science applications through directed evolution.

Aside from his role at Kapa, Mr. McEwan was also instrumental in founding Agencourt Bioscience and Agencourt Personal Genomics. These enterprises collectively achieved an impressive exit value exceeding $700 million, underscoring his knack for creating commercially viable life-science companies. His track record demonstrates not only his entrepreneurial spirit but also his ability to generate significant returns from early-stage ventures.

Engagement in Angel Investing

Beyond founding companies, McEwan has taken on an active role as an angel investor, focusing on early-stage ventures in life science tools and diagnostics. He currently chairs the boards of DNA Script and SeqWell, while also serving on the boards of other promising companies like Watchmaker Genomics and Codetta Bio. His extensive network and industry knowledge position him as a valuable asset to CS Genetics as it seeks to advance its pioneering initiatives in single-cell genomics.

Commitment to Advancing Genomics

Bill Colston, the CEO of CS Genetics, expressed enthusiasm about McEwan's board appointment, emphasizing how his deep-rooted experience in genomics and strategic growth would greatly aid the company’s mission to democratize single-cell genomics. The goals of CS Genetics revolve around making genomic insights more accessible and scalable, particularly through its innovative technologies.

About CS Genetics

Based in San Diego, California, CS Genetics is a privately-owned genomics technology company world-renowned for its groundbreaking innovations. The company has developed an unprecedented instrument-free platform tailored for single-cell genomics. This technology leverages a unique process known as Kinetic Confinement that distinguishes itself from other existing single-cell methods. This advancement not only simplifies and accelerates cellular analysis but also seamlessly integrates with standard laboratory infrastructures, making it a compelling option for many researchers and institutions.

Furthermore, CS Genetics holds a significant portfolio of global intellectual property concerning its platforms and workflows, alongside related reagents and applications. The company looks to usher in a new era of NGS-based cellular analysis, presenting a brighter future for genomic research and its applications.

For more updates on CS Genetics and its achievements, please visit CS Genetics.